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The L1CAM antibody A10-A3 efﬁciently reduces tumor growth in a nude mouse model. Here, we
describe the crystal structure of the Fab fragment of A10-A3 determined at 2.0 angstrom resolution.
The A10-A3 antibody H3 loop reveals a characteristic arrangement of exposed aromatic residues that
may play an important role in antigen binding. A structure model of the complex between L1CAM
Ig1-4 and A10-A3 Fab indicates that the Fab binds to three small loops outside Ig1 and a residue
between Ig1 and Ig2, consistent with an epitope mapping result. The data presented here should
contribute to the design of high-afﬁnity antibody for therapeutic purposes as well as to the under-
standing of neural cell remodeling and cancer progression mechanism mediated by L1CAM.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction in cancerous tissues and rarely in normal tissues, in addition to itsThe major cell adhesion molecule families (integrins, cadherins,
immunoglobulin-like CAMs and selectins) are often aberrantly
regulated in human cancer, contributing to the progression of can-
cers [1]. One such molecule L1CAM was reported in recent years to
be involved in the formation of variety of human cancers [2].
L1CAM, which is a type I transmembrane glycoprotein of the
immunoglobulin superfamily and originally described as a neural
cell adhesion molecule, has been shown to initiate a variety of dy-
namic motile processes, including cerebella cell migration and
neurite extension in the central nervous system [3]. While
L1CAM is expressed in a wide variety of human cancers, its pres-
ence in normal tissues was observed only in the nervous system
and in a small number of other tissues including lymphoid and
myelomonocytic cells [4], kidney tubule epithelial cells [5], and
intestinal crypt cells [6]. The feature of L1CAM expression, mostlychemical Societies. Published by E
Hong), ryuse@hanyang.ac.kr
lly to this work.cell surface localization, makes L1CAM a useful target in the diag-
nosis of patients with advanced stages of cancer, and a potential
candidate for therapeutic intervention.
L1CAM is composed of an 1100-residue ectodomain contain-
ing six Ig-like domains followed by ﬁve ﬁbronectin type III (FNIII)
repeats, a single-pass transmembrane region, and a 114-residue
cytoplasm tail (Fig. 1) [7]. Based on the crystal structure of two
L1CAM homologs, hemolin [8] and axonin-1 [9], the four N-termi-
nal Ig-like domains of L1CAM are predicted to adopt a horseshoe-
shaped conformation in which the ﬁrst and second domains (Ig1
and Ig2) fold back to interact with the fourth and third domains
(Ig4 and Ig3), respectively (Fig. 1). The ﬁrst four domains of
L1CAM and related proteins are necessary and sufﬁcient for hom-
ophilic interaction [10].
Antibodies blocking integrins, cadherins, selectins and IgG
superfamily adhesion molecules have been developed as anti-can-
cer agents [11]. A monoclonal antibody against L1CAM inhibited
migration and growth of tumor cells in vitro and in human ovarian
carcinoma xenograft models [12–14]. In our previous study, we
generated an anti-L1CAM monoclonal antibody A10-A3 by
immunizing mice with human intrahepatic cholangiocarcinomalsevier B.V. All rights reserved.
Fig. 1. The domain structure of L1CAM, showing the six Ig domains, the ﬁve FNIII domains, the transmembrane domain and the cytoplasmic domains. In the CAM
superfamily, L1 is distinguished by its long N terminus and extra residues in the Ig2-3 loop enabling the horseshoe structure. Ig1-4 domains are color-coded consistently
throughout the ﬁgures.
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cells and inhibits the tumor growth in nude mice [15], suggesting
that A10-A3 may have a potential as an anti-cancer agent.
In the present study, to understand a structural mechanism of
the antitumor activity exerted by A10-A3, we have determined
the crystal structure of the Fab of the A10-A3 to 2.0 Å resolutions,
and constructed a complex structure model with the L1CAM Ig1-4
based on a homology model of L1CAM Ig1-4. The complex model
indicates that three small loops from the L1CAM Ig1 interact with
the antigen binding site of the A10-A3 Fab. The interaction be-
tween the Ig1-Ig2 loop of L1 and the Fab CDR L2 also stabilizes
the complex. We also performed epotope mapping with deletion
mutants of L1CAM and identiﬁed that A10-A3 binds to the
L1CAM Ig1 domain, consistent with the structural modeling. The
detailed structural information on the CDR loops and framework
regions will be useful in the afﬁnity maturation and humanization
studies for the antibody’s therapeutic applications.
2. Materials and methods
2.1. Preparation of A10-A3 Fab fragment
A10-A3 antibody was puriﬁed from the culture supernatants of
hybridomas by an afﬁnity chromatography on Protein G-Sepharose
column (Upstate, USA). The puriﬁed antibody was digested with
papain (Pierce, USA) according to the manufacturer’s instruction
and the Fc part was removed by a Protein A-agarose column (Up-
state) to obtain the A10-A3 Fab. Finally, the Fab was puriﬁed by
an afﬁnity chromatography using CNBr-activated Sepharose (GE
Life Sciences) coupled with the Ig1 domain of L1CAM. The purity
of the Fab was conﬁrmed by SDS–PAGE. The puriﬁed Fab was dia-
lyzed against 1X PBS, pH 7.4 and concentrated to 20 mg/ml for
crystallization.
2.2. Crystallization and diffraction data collection
Crystallization condition was screened with the sitting drop
method by using the Hampton screening kit (index and crystal
screen I&II) at 18 C. An aliquot (1.0 ll) of the protein was mixed
with an equal volume of a reservoir solution. Crystals grew at the
condition of 0.2 M MgCl2, 0.1 M bis-tris pH 5.5 and 25% PEG3350
after 3–4 days. The cryo-protectant contained the mother liquor
with 20% glycerol. Crystals were harvested and soaked in the
cryo-protectant and then ﬂash-frozen in a nitrogen stream. The dif-
fraction data were collected in the beamline 6C at the Pohang
Accelerator Laboratory and processed with the HKL2000 program
[16]. The crystal belonged to the P212121 space group with unit cell
dimensions of a = 41.19 Å, b = 71.78 Å and c = 127.66 Å.
2.3. Structure determination and reﬁnement
The structure of A10-A3 Fab was determined by molecular
replacement by using the program Molrep [17]. The murine
anti-retinol-binding protein (RBP) Fab (PDB code 3BSZ) [18] that
showed the highest sequence homology with A10-A3 Fab was usedas the search model. The structure was reﬁned by using the
programs Refmac [19] and CNS [20]. During the reﬁnement, the ran-
domly selected 5%of datawere set aside forRfree calculation.Manual
model building and adjustments were performed by using the
program Coot [21]. The Ramachandran plots were drawn by the
program PROCHECK [22]. Figures were drawn by using the program
Pymol [23].
3. Results and discussion
The A10-A3 Fab structure determined by molecular replace-
ment comprises 216 residues of the light (L) chain and 218 resi-
dues of the heavy (H) chain with a total of 330 water molecules.
The ﬁnal Rcryst and Rfree values for the model reﬁned at 2.0
angstrom resolutions are 15.8% and 18.9%, respectively. The reﬁne-
ment statistics of the ﬁnal structure are summarized in Supple-
mentary Table 1. The Ramachandran plot [24] showed that 97.7%
of residues were in the favored regions, 2.1% of residues in the al-
lowed regions, and only one residue (R72) representing 0.2% of the
total number, in the outlier regions.
The A10-A3 Fab has the canonical b-sandwich immunoglobulin
fold with four domains: VL, CL, VH, and CH1 (where V indicates a
variable domain; C indicates a constant domain). The elbow angle
of the A10-A3 Fab is 135.8 that falls within the range of 127–225
commonly observed for Fab molecules. The CDRs L1, L2, and L3
conform to the canonical conformations belonging to the classiﬁca-
tions jL1-4, L2-1, and jL3-1 [25], respectively. The CDRs H1 and
H2 belong to canonical classes H1-1 and H2-2A [25], respectively.
The CDR H3 has a large variety in its length and amino acid se-
quence, and thus no canonical structures have ever been estab-
lished. According to a CDR H3 classiﬁcation [26], the A10-A3 CDR
H3 can be classiﬁed as an extended base structure together with
a b-hairpin conformation. In the A10-A3 H3, many side chains of
the H3 loop extend towards outside the loop, so the main chain
atoms become close together and form a hydrogen bond ladder.
The A10-A3 H3 is eleven residue-long, which is considered a mod-
erate length. This loop is abundant of aromatic residues with four
tyrosines and one phenylalanine out of eleven residues. A study of
the antigen-antibody complex structures indicates that aromatic
residues play a dominant role in antigen binding [27]. Two of the
aromatic residues in the A10-A3 H3 loop (Y99 and F105) are buried
in the cavity formed by the six CDR loops, another two aromatic
side chains (Y100 and Y107) are projected outside the cavity, while
another aromatic residue Y102 is on the top of the loop, which may
form part of the interaction of the antibody with its antigen (Fig. 2).
A comparative study of structural [26] diversity of CDR H3 revealed
that three out of ten antibodies display signiﬁcant structural differ-
ences between the free and complex forms. However, the free
forms of all the three antibodies lack typical hydrogen bond lad-
ders in their b-hairpins, indicating that the A10-A3 H3 loop is not
likely to have structural changes during antigen binding.
To better understand the interaction of antibody and antigen, we
constructed a homologymodel of of L1CAM Ig1-4 (residues 35-422)
(Fig. 3) based on the previous structure of CNTN4 Ig1-4 [28]. The
Ramachandran plot of the resulting homology model showed
Fig. 2. The ﬁnal electron-density map of the CDR-H3 loop (residues 97-107). The rA weighted [32] (2|Fo|  |Fc|) electron-density map was phased using the ﬁnal model at
2.0 Å resolution. The map is contoured at 1.0r. The ﬁnal model is shown as a stick model. All the residues except T97 and G104 were not conserved in the target antibody. The
sequence of the A10-A3 H3 is TVYYGYDGFAY, whereas the sequence of the target antibody is TRSGFDYGNED.
Fig. 3. (A) The homology model of L1CAM Ig1-4 showing the horseshoe-shaped structure of the domains. Three small loops (marked with 1, 2 and 3) of Ig1 domain make
contacts with the CDR regions of A10-A3 in the complex structure. (B) The complex model of hL1CAM Ig1-4 and A10-A3 Fab. Shown in the ﬁgure are only light and heavy
chain variable regions for clear viewing. The three loops interacting with the A10-A3 CDRs are marked with 1, 2 and 3 as in A. The Ig domains are color coded as in Fig. 1, and
the long Ig2-Ig3 linker is in blue. Fab variable region and CDR regions are shown in yellow and magenta, respectively.
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lowed regions, and 3.9% in the disallowed regions. Of the 3.9% of the
residues in the disallowed region, many were in either loop regionsor regions of low homology. Compared with the experimentally
determined structure of CNTN4, the rmsd calculated by using the
CE server [29], was 0.9 Å, which lies in the acceptable range for
Fig. 4. Binding mode of L1CAM Ig1-4 and A10-A3 Fab. The key residues were mapped on hL1 Ig1 and CDR regions of light and heavy chain of Fab. The hL1 Ig1 and Fab are
colored green and yellow, respectively. The CDR regions of light and heavy chain are colored pink and magenta, respectively. The labeling for hL1 and Fab is colored blue and
black, respectively. Hydrogen bonds were found by using the program Pymol [23]. (A) Interactions between the ﬁrst Ig1 loop and the Fab heavy chain CDR loops; (B)
interactions between the second and third Ig1 loop and the Fab light chain CDR loops L3; (C) interactions between the third Ig1 loop and the Fab heavy chain CDR H3; (D)
interactions between the loop Ig1-2 and the Fab light chain CDR L2.
Fig. 5. Epitope mapping of A10-A3. The extracellular region and the truncated variants of L1CAM fused to the human IgG Fc (hFc) were expressed in HEK293T cells and the
culture supernatants containing 5 lg proteins were subjected to Western blot analysis using A10-A3 followed by anti-mouse IgG-HRP (A) or anti-hFc-HRP (B).
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notable feature is its almost globular or horseshoe-shape structure,
in which Ig1 lies opposed to Ig4 and Ig2 lies opposed to Ig3 in an
anti-parallel fashion (Fig. 3). This folded structure is enabledby a lin-
ear stretch of amino acids between Ig2 and Ig3, shown in blue, that is
unique to the horseshoe shaped structures [31].
For the prediction of the complex structure by docking, the A10-
A3 Fab and hL1 Ig1-4 structures were submitted to the ClusPro ser-
ver as receptor and ligand, respectively. The antibody mode was
chosen in the docking. A total of 25 complex models were pre-
dicted, in which the ﬁrst model (model 0) with the lowest free-en-
ergy and largest number of wide free-energy attractor (202
members) showed the interaction between the Fab and the hL1
Ig1 (Fig. 3). In the complex model, the A10-A3 Fab CDR loops inter-
acted mainly with three small loops of the hL1 Ig1 domain and a
residue in the Ig1-2 loop (Fig. 4). All other models indicated inter-actions with other domains. The Ramachandran plot of the com-
plex model showed that 89.1% of all residues were in the most
favored regions, 8.2% of the residues were in the allowed regions,
and 2.7% of the residues were in the disallowed regions.
To experimentally characterize the domain to which A10-A3
binds, to begin with, the extracellular region, Ig1-6, and Fn1-5 of
L1CAM were separately expressed as fusion proteins with the hu-
man IgG Fc and subjected to Western blot analysis using A10-A3
(Fig. 5A) and anti-human IgG (Fc speciﬁc)-HRP (Fig. 5B). The result
indicates that A10-A3 binds to the Ig domains, but not to the Fn do-
mains. Next, the Ig-like domains were serially deleted, expressed
as a fusion form with the Fc, and subjected to Western blot analy-
sis. A10-A3 bound to the Ig1-5, Ig1-4, Ig1-3, Ig1-2, and Ig1, but not
to the Ig2-6, indicating that A10-A3 binds to the Ig1 domain of
L1CAM speciﬁcally, consistent with the model of the complex
between L1CAM and A10-A3 (Fig. 3).
Fig. 6. Models for homophilic adhesion of L1CAM and antibody-L1CAM complex. (A) A zipper model for homophilic adhesion based on the packing of unglycosylated axonin-
1 horseshoes in crystals [9]. (B) Model of L1CAM homophilic adhesion interaction and antibody binding, generated by aligning L1 Ig1-4 to axonin-1 and its symmetry
molecules. The black line in A indicates the remaining Ig-like, ﬁbronectin type III, and transmembrane domains of L1CAM. Ig, Ig0 , Ig0 0 and Ig0 0 0 indicate different L1 Ig1-4
molecules, and colored in orange, magentas, green and green, respectively. The loop from Ig3 contributes to homophilic interaction is colored in blue. A10-A3 Fab was colored
in cyan. The point of view in B is looking down from the upper cell membrane of A.
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that two of the horseshoe-shaped molecules arrange with antipar-
allel long axes so that the edge of one molecule contacts the face of
the other (Fig. 6A). In the modeled homophilic complex (Fig. 6B),
the ﬁrst molecule of Fab is able to bind the homophilic complex
of L1CAM. However, the second Fab can not bind to the complex
due to steric hindrance between Fab molecules. The Fc region of
the A10-A3 antibody would prohibit binding of the second anti-
body molecule, too. Thus, we expect that the A10-A3 binding to
L1CAM would decrease an efﬁcient homophilic interaction. In fact,
A10-A3 inhibited the homophilic L1CAM binding in trans in a dose-
dependent manner (H.J.H. and E.S.L., unpublished results). The de-
tailed understanding of L1CAM interaction with A10-A3 should
await experimental determination of crystal structures of the
complexes.
In summary, we determined the crystal structure of the Fab
fragment of A10-A3 antibody against L1CAM and constructed a
complex model between the A10-A3 Fab and L1CAM Ig1-4 by using
a homology model of L1CAM Ig1-4. The Fab structure revealed ex-
posed hydrophobic residues in the CDR H3 loop and a concave
antigen binding surface. In the complex model, three small loops
of Ig1 domain and one residue between Ig1 and Ig2 interact with
CDR loops of Fab. The detailed information on the CDR loop confor-
mation and framework regions should be useful for the antibody
afﬁnity maturation and humanization for the therapeutic applica-
tion of the A10-A3 antibody.Acknowledgments
This work was supported by a Hanyang University faculty
Grant, a Ministry of Science and Technology (Korea) Grant
(C1007150-01-01), a Kangwon National University Grant, a KRIBB
research initiatives grant and a high ﬁeld NMR Research Program
of KBSI. We thank Dr. K.J. Kim (PAL BL6C) and staffs for help with
data collection.Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.febslet.2010.11.028.References
[1] Raveh, S., Gavert, N. and Ben-Ze’ev, A. (2009) L1 cell adhesion molecule
(L1CAM) in invasive tumors. Cancer Lett. 282, 137–145.
[2] Schäfer, M.K. and Altevogt, P. (2010) L1CAM malfunction in the nervous
system and human carcinomas. Cell. Mol. Life Sci. 67, 2425–2437.
[3] Rathjen, F.G. and Schachner, M. (1984) Immunocytological and biochemical
characterization of a new neuronal cell surface component (L1 antigen) which
is involved in cell adhesion. EMBO J. 3, 1–10.
[4] Pancook, J.D., Reisfeld, R.A., Varki, N., Vitiello, A. and Fox, R.I. (1997)
Montgomery AMP. Expression and regulation of the neural cell adhesion
molecule L1 on human cells of myelomonocytic and lymphoid origin. J.
Immunol. 158, 4413–4421.
[5] Debiec, H., Christensen, E.I. and Ronco, P.M. (1998) The cell adhesion molecule
L1 is developmentally regulated in the renal epithelium and is involved in
kidney branching morphogenesis. J. Cell Biol. 143, 2067–2079.
[6] Thor, G., Probstmeier, R. and Schachner, M. (1987) Characterization of the cell
adhesion molecules L1, NCAM and J1 in the mouse intestine. EMBO J. 6, 2581–
2586.
[7] Hortsch, M. (1996) The L1 family of neural cell adhesion molecules: old
proteins performing new tricks. Neuron 17, 587–593.
[8] Su, X.D., Gastinel, L.N., Vaughn, D.E., Faye, I., Poon, P. and Bjorkman, P.J. (1998)
Crystal structure of hemolin: a horseshoe shape with implications for
homophilic adhesion. Science 281, 991–995.
[9] Freigang, J., Proba, K., Leder, L., Diederichs, K., Sonderegger, P. and Welte, W.
(2000) The crystal structure of the ligand binding module of axonin-1/TAG-1
suggests a zipper mechanism for neural cell adhesion. Cell 101, 425–433.
[10] Haspel, J., Friedlander, D.R., Ivgy-May, N., Chickramane, S., Roonprapunt, C.,
Chen, S., et al. (2000) Critical and optimal Ig domains for promotion of neurite
outgrowth by L1/Ng-CAM. J. Neurobiol. 42, 287–302.
[11] Lafrenie, R.M., Bruckner, C.A. and Bewick, M.A. (2007) Cell adhesion and
cancer: is there a potential for therapeutic intervention. Expert Opin. Ther.
Targets 11, 727–731.
[12] Primiano, T., Baig, M., Maliyekkel, A., Chang, B.D., Fellars, S., Sadhu, J., et al.
(2003) Identiﬁcation of potential anticancer drug targets through the selection
of growth-inhibitory genetic suppressor elements. Cancer Cell 4, 41–53.
[13] Arlt, M.J., Novak-Hofer, I., Gast, D., Gschwend, V., Moldenhauer, G., Grünberg,
J., et al. (2006) Efﬁcient inhibition of intra-peritoneal tumor growth and
dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell
adhesion molecule monoclonal antibody treatment. Cancer Res. 66, 936–943.
[14] Knogler, K., Grünberg, J., Zimmermann, K., Cohrs, S., Honer, M., Ametamey, S.,
et al. (2007) Copper-67 radioimmunotherapy and growth inhibition by anti-
L1- cell adhesion molecule monoclonal antibodies in a therapy model of
ovarian cancer metastasis. Clin. Cancer Res. 13, 603–611.
[15] Min, J.K., Kim, J.M., Li, S., Lee, J.W., Yoon, H., Ryu, C.J., et al. (2010) L1 cell
adhesion molecule is a novel therapeutic target in intrahepatic
cholangiocarcinoma. Clin. Cancer Res. 16, 3571–3580.
[16] Otwinowski, Z. and Minor, W. (1997) Processing of X-ray diffraction data
collected in oscillation mode. Methods Enzymol. 276 (Pt A), 307–326.
[17] Vagin, A. and Teplyakov, A. (1997) MOLREP: an automated program for
molecular replacement. J. Appl. Cryst. 30, 1022–1025.
[18] Zanotti, G., Folli, C., Cendron, L., Alﬁeri, B., Nishida, S.K., Gliubich, F., et al.
(2008) Structural and mutational analyses of protein-protein interactions
between transthyretin and retinol-binding protein. FEBS J. 275, 5841–5854.
158 C.H. Wei et al. / FEBS Letters 585 (2011) 153–158[19] Murshudov, G.N., Vagin, A.A. and Dodson, E.J. (1997) Reﬁnement of
macromolecular structures by the maximum-likelihood method. Acta
Crystallogr. D. Biol. Crystallogr. 53, 240–255.
[20] Brunger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P., Grosse-
Kunstleve, R.W., et al. (1998) Crystallography & NMR system: A=a new
software suite for macromolecular structure determination. Acta Crystallogr.
D 54, 905–921.
[21] Emsley, P. and Cowtan, K. (2004) Coot: model-building tools for molecular
graphics. Acta Crystallogr. D. Biol. Crystallogr. 60, 2126–2132.
[22] Laskowski, R.A., McArthur, M.W., Moss, D.S. and Thornton, J.M. (1993)
PROCHECK: a program to check the stereochemical quality of protein
structures. J. Appl. Crystallogr. 26, 283–291.
[23] DeLano, W.L. The PyMOL Molecular Graphics System on World Wide Web
http://www.pymol.org.
[24] Ramachandran, G.N. and Sasisehharan, V. (1968) Conformation of polypeptides
and proteins. Adv. Protein Chem. 23, 283–437.
[25] Al-Lazikani, B., Lesk, A.M. and Chothia, C. (1997) Standard conformations
for the canonical structures of immunoglobulins. J. Mol. Biol. 273, 927–
948.[26] Shirai, H., Kidera, A. and Nakamura, H. (1996) Structural classiﬁcation of CDR-
H3 in antibodies. FEBS Lett. 399, 1–8.
[27] Vargas-Madrazo, E., Lara-Ochoa, F. and Almagro, J.C. (1995) Canonical
structure repertoire of the antigen-binding site of immunoglobulins
suggests strong geometrical restrictions associated to the mechanism of
immune recognition. J. Mol. Biol. 254, 497–504.
[28] Bouyain, S. and Watkins, D.J. (2010) The protein tyrosine phosphatases PTPRZ
and PTPRG bind to distinct members of the contactin family of neural
recognition molecules. Proc. Natl. Acad. Sci. 107, 2443–2448.
[29] Shindyalov, I.N. and Bourne, P.E. (1998) Protein structure alignment by
incremental combinatorial extension (CE) of the optimal path. Protein Eng. 11,
739–747.
[30] Krieger, E., Nabuurs, S.B. and Vriend, G. (2003) Homology modeling. Methods
Biochem. Anal. 44, 509–523.
[31] Haspel, J. and Grumet, M. (2003) The L1CAM extracellular region: a
multidomain protein with modular and cooperative binding modes. Front
Biosci. 8, s1210–s1225.
[32] Read, R.J. (1986) Improved Fourier coefﬁcients for maps using phases from
partial structures with errors. Acta Cryst. A 42, 140–149.
